20196-81-0

Upstream product

• 100-52-7 benzaldehyde 
• 24332-89-6 methyl-(α-D-lyxo-3-deoxy-hexopyranoside) 
• 2880-96-8 methyl 2,3-anhydro-4,6-dioxabenzylidene-α-D-talopyranose 
• 86420-78-2 methyl 2,3-anhydro-4,6-O-benzylidene-β-D-talopyranoside 
• 1125-88-8 benzaldehyde dimethyl acetal 
• 29581-42-8 methyl 3-deoxy-α-D-galactopyranoside 
• 1186196-12-2 methyl 2-O-benzoyl-4,6-O-benzylidene-3-deoxy-α-D-galctopyranoside 
• 2880-96-8 (1aR,2S,6R,7aR,7bR)-2-Methoxy-6-phenyl-hexahydro-1,3,5,7-tetraoxa-cyclopropa[a]naphthalene 
• 16697-40-8 methyl-[O⁴,O⁶-((S)-benzylidene)-S-methyl-3-thio-β-D-idopyranoside] 

Downstream Products

• 56405-85-7 methyl-[O⁴,O⁶-((S)-benzylidene)-O²-methyl-α-D-lyxo-3-deoxy-hexopyranoside] 
• 56405-85-7 methyl-[O⁴,O⁶-((S)-benzylidene)-O²-methyl-β-D-lyxo-3-deoxy-hexopyranoside] 

Relevant academic research and scientific papers

Synthesis and evaluation of 3″- and 4″-deoxy and -fluoro analogs of the immunostimulatory glycolipid, KRN7000

Four 3″- and 4″-deoxy and -fluorogalactosyl ceramides were synthesized, and their ability to stimulate iNKT cells, based on levels of IL-2 production, was assessed in three NKT cell receptor hybridomas. In two of the hybridomas, 1.2 and 2H4, all of the analogs were immunostimulatory, while in the 1.4 hybridoma only the 4″-fluoro analog led to the production of significant levels of IL-2.

Synthesis of methyl O-α-L-rhamnopyranosyl-(12)-α-D-galactopyranosides specifically deoxygenated at position 3, 4, or 6 of the galactose residue

The title disaccharides were synthesized by condensation of 2,3,4-tri-O-benzoyl-α-L-rhamnopyranosyl bromide with suitably protected, deoxygenated derivatives of methyl α-D-galactopyranoside.Deoxygenation was achieved via activation of a protected methyl α